Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Slides
Videos-PodcastsVideos & Podcasts

Quicksearch

Trial endpoint vs. therapeutic objectivesECCO'17 Barcelona
Year: 2017
Authors: Baert F.
Outcome measures, Patient reported outcomes, Histological remission, Disease activity indices, Mucosal healing
Files: 1
Ustekinumab15th IBD Intensive Advanced Course
Year: 2017
Authors: Ferrante M.
Crohn's disease, Disease activity Indices, Ustekinumab, Colonoscopy
Files: 1
Vedolizumab15th IBD Intensive Advanced Course
Year: 2017
Authors: Lindsay J.
Therapeutic drug monitoring, Vedolizumab
Files: 1
Vedolizumab in children and other biologics after TNF – what can we extrapolate? A case-based discussion4th P-ECCO Educational Course
Year: 2017
Authors: Escher H.
Ustekinumab, Vedolizumab, Paediatric
Files: 1
Workshop 1 – UC Management (Group A)8th N-ECCO School
Year: 2017
Authors: Sturm A.
Ulcerative colitis, Infliximab, Thiopurines (AZA / MP), Vedolizumab, Corticosteroids, 5-ASA
Files: 1
Workshop 2 – CD Management (Group B)8th N-ECCO School
Year: 2017
Authors: Hindryckx P.
Anti TNF drug levels, Anti drug antibodies, Calprotectin, Therapeutic drug monitoring, IBD Nurse, Anti-TNF agents, Corticosteroids, Ustekinumab, Vedolizumab, IBD in pregnancy, Anaemia, Iron deficiency, Etrolizumab, Filgotinib, Mongersen
Files: 1